Comparison of Aprepitant Versus Aprepitant and Transdermal Scopolamine for Preventing Postoperative Nausea and Vomiting

• Status: Completed
• Trial end date: 2010-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to compare the incidence of nausea, vomiting, need for rescue medication, prolonged PACU time, and unplanned hospital admission in patients with high risk for post-operative nausea and vomiting (PONV) treated with oral aprepitant with or without transdermal scopolamine preoperatively.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Drexel University
• Collaborator: Merck Sharp & Dohme Corp.
• Treatments: Aprepitant; Butylscopolammonium Bromide; Fosaprepitant; Scopolamine; Scopolamine Hydrobromide

Criteria

Inclusion Criteria:

• Between 18 and 65 years of age

• American Society of Anesthesiology (ASA) physical status 1-3

• If on oral contraceptive, must be willing to use back up method for 1 month

• Must have 2 risk factors for PONV

Exclusion Criteria:

• History of vomiting due to middle ear infection, nervous system disorder, or other condition

• Procedure less than 1 hour

• Pregnant or breast feeding

• Antiemetic medication in previous 24 hours

• Narrow-angle glaucoma

• Allergic to belladonna alkaloids

• Hypersensitive to barbiturates

• Prostate hypertrophy

• Severe hepatic disease

• On chemotherapy taking aprepitant

• Fever

• Sepsis

• Taking any of the following medications: Orap, Seldane, Hismanal, Propulsid, Phenytoin, Phenothiazines, Tricyclic antidepressants, Meperidine, Tolbutamide, Aluminum and Magnesium containing Antacids, Anti-cholinergics, Coumadin